美国的疫苗在瓜地马拉获得首个拉丁美洲批准. GC Biopharma receives first Latin American approval for its varicella vaccine in Guatemala.

韩国生物制药公司GC Biopharma已在危地马拉获得疫苗"巴瑞斯拉 (BARYCELA) "的营销许可. South Korean biopharmaceutical company GC Biopharma has received marketing authorization for its varicella vaccine, BARYCELA Inj., in Guatemala. 这标志着该疫苗在拉丁美洲首次获得监管部门的批准,这是公司区域扩张的一个重要步骤. This marks the first regulatory approval for the vaccine in Latin America, a significant step in the company's regional expansion. 该疫苗使用专有MAV/06菌株开发,并被世界卫生组织认可与其他基于Oka菌株的疫苗可以互换. The vaccine is developed using a proprietary MAV/06 strain and is recognized by the World Health Organization as interchangeable with other Oka strain-based vaccines.